| 摘要: |
| 目的 研究护肝片(HGT)及其拆方(DR)对慢性肝损伤肝阴虚证大鼠模型的影响。方法 54只Wistar大鼠随机分为7组,除正常组外,其余6组均造模共6周,建立慢性肝损伤肝阴虚证的大鼠模型,然后后开始给予相应的药物灌胃治疗,每日1次,共2周。末次给药后处死动物,采集大鼠血清和肝组织标本。检测血清丙氨酸氨基转移酶(ALT)、白蛋白(ALB)、醛固酮(ALD)、肝组织匀浆超氧化物歧化酶(SOD)、丙二醛(MDA)以及肝组织羟脯氨酸(HYP)含量。HE染色法对肝组织病理学形态检查。结果 与模型组比较,护肝片全方组使血清中丙氨酸氨基转移酶、醛固酮、肝丙二醛、肝组织羟脯氨酸明显降低,人血白蛋白和肝超氧化物歧化酶明显升高,护肝片全方组作用优于各拆方组,对肝功能和组织病理学形态及该模型具有的肝阴虚证有所改善。结论 护肝片全方比各拆方组作用效果更好,可以改善肝阴虚症状,清除自由基,减少纤维化形成,对肝有一定的保护作用。 |
| 关键词: 四氯化碳 温中药 肝损伤 肝纤维化 |
| DOI:10.13506/j.cnki.jpr.2016.05.003 |
| 基金项目: |
|
|
|
| Study of Hugan Tablets and its decomposed recipes on rat model of yin-deficiency syndrome of liver in the chronic hepatic injury |
| YI Shaoling,ZHU Cuixia,YU Zejun,CHEN Lingli |
| (Experiment and Practice Training Center, Guangdong Food and Drug Vocational College,Guangzhou 510520,China) |
| Abstract: |
| Objective To investigate the effect of decomposed recipes of Hugan Tablets on liver yin-deficiency syndrome rat model within the chronic hepatic injury. Methods 45 Wistar rats were divided into seven groups.Except the dissolvent groups,the other groups were reduced to liver yin-deficiency syndrome rat model for 6 weeks.Then the rats were treated for 2 weeks.Rats were sacrificed after the last administration, and the serum and liver tissue were taken.The contents of ALT, ALB,ALD in serum were measured.HYP,MDA,SOD activity in liver were determined.Pathological changes of liver tissue were determined by HE staining.Results Compared with the model group,Hugan Tablets groups significantly decreased the activities of ALT and ALD in serum and increased the level of ALB.Meanwhile,Hugan Tablets also decreased the contents of MDA and HYP and reinforced SOD activity in liver tissue.The effect of Hugan Tablets was better than the effect of its decomposed recipes.Conclusion The effect of Hugan Tablets group was more effective than the effect of its decomposed recipes groups.Hugan Tablets can significantly improve yin-deficiency syndrome,change pathological injury of liver tissue,scavenge free radicals and reduce the probability of hepatic fibrosis occurrence. |
| Key words: Carbon tetrachloride Interior warming drugs Hepatic injury Hepatic fibrosis |